section name header

Evidence summaries

Eradication of Helicobacter Pylori for Non-Ulcer Dyspepsia

Helicobacter pylori eradication has a small benefit in the treatment of non-ulcer dyspepsia (NNT = 14). Level of evidence: "A"

A Cochrane review [Abstract] 1 [withdrawn from publication] included 21 RCTs.

Eighteen trials compared antisecretory dual or triple therapy with placebo antibiotics ± antisecretory therapy, and evaluated dyspepsia at 3-12 months. Seventeen of these trials gave results as dichotomous outcomes evaluating 3 566 patients and there was no significant heterogeneity between the studies. There was a 10% relative risk reduction in the H. pylori eradication group (95% CI 6% to 14%) compared to placebo. The number needed to treat to cure one case of dyspepsia = 14 (95% CI 10 to 25). A further three trials comparing bismuth based H pylori eradication with an alternative pharmacological agent suggested that H pylori eradication was more effective than either H2 receptor antagonists or sucralfate in treating non-ulcer dyspepsia.

References

  • Moayyedi P, Soo S, Deeks JJ et al. WITHDRAWN: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2011;(2):CD002096. [PubMed]

Primary/Secondary Keywords